Circulating tumor cells (CTCs) are cells that have shed into the vasculature or lymphatics from a primary tumor and are carried around the body in the circulation. Circulating tumor cells (can be detected in the circulation, where the detection of CTCs in blood can provide prognostic information. Advanced technologies emerge to characterize CTCs at the molecular level, where the biological information can be obtained in real time. There is a great potential of CTCs to be used as pharmacodynamics and predictive biomarkers and potentially their use in revealing drug resistance in real time. Monitoring CTCs predicts the metastatic tumor progression in prostate, breast, colorectal, lung, ovarian and pancreatic cancer.
The global circulating tumor cells prognostic technologies market segmentation is based on technology tumor cell enrichment, centrifugation, filtration, immunological methods, tumor cell detection, molecular methods, optical methods), and its application (breast cancer, colorectal cancer, prostate cancer, lung cancer, ovarian cancer and pancreatic cancer, etc.).
The global circulating tumor cells prognostic technologies market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global circulating tumor cells prognostic technologies market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global circulating tumor cells prognostic technologies market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global circulating tumor cells prognostic technologies market and included in this report are AdnaGen AG, Advanced Cell Diagnostics, Inc., AVIVA BioSciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc., Silicon Biosystems, S.p.A., Veridex, LLC, Vitatex, Inc. and others.